More about
Insertion-Mutated Non-Small Cell Lung Cancer
News
December 01, 2023
3 min watch
Save
VIDEO: New first-line treatment ‘potentially practice-changing’ in lung cancer subset
MADRID — Hossein Borghaei, DO, MS, discussed results from the PAPILLON trial, which combined amivantamab and chemotherapy as first-line treatment for EGFR exon 20 insertion-mutated non-small cell lung cancer, in a video interview.